MedTrace Logo

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

NCT00493454 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2013-05-31

Study results available
· View outcomes & findings →

Summary

Primary Objective:

* Overall Response Rate (ORR).

Secondary Objectives:

* The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders.
* Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses (PR).
* Time to next anticancer therapy (TTNT).

Conditions

Interventions

DRUG

Zevalin

.3 mCi IV Over 10 Minutes x 1 Day

DRUG

Rituximab

250 mg/m\^2 IV Over 6 to 8 Hours

DRUG

^111 In Ibritumomab Tiuxetan

1.6 mg IV Over 10 Minutes x 1 Day

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Felipe Samaniego, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493454 on ClinicalTrials.gov